Empirical Finance LLC Raises Holdings in Hologic, Inc. (NASDAQ:HOLX)

Empirical Finance LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,473 shares of the medical equipment provider’s stock after buying an additional 147 shares during the period. Empirical Finance LLC’s holdings in Hologic were worth $690,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Cetera Investment Advisers lifted its holdings in shares of Hologic by 188.9% during the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after purchasing an additional 13,380 shares during the last quarter. Clearbridge Investments LLC grew its holdings in Hologic by 51.4% in the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock valued at $40,430,000 after purchasing an additional 176,006 shares during the period. Andra AP fonden increased its holdings in Hologic by 224.5% in the 2nd quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock worth $7,083,000 after acquiring an additional 66,000 shares in the last quarter. Swedbank AB grew its position in shares of Hologic by 5.2% in the second quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock valued at $121,060,000 after purchasing an additional 80,575 shares during the period. Finally, National Bank of Canada FI grew its position in shares of Hologic by 352.0% in the first quarter. National Bank of Canada FI now owns 299,098 shares of the medical equipment provider’s stock valued at $22,474,000 after purchasing an additional 232,928 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Up 1.4 %

Shares of HOLX opened at $78.60 on Friday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The firm has a 50-day moving average price of $80.71 and a 200 day moving average price of $78.25. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The firm has a market capitalization of $18.26 billion, a P/E ratio of 23.60, a P/E/G ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter last year, the firm earned $0.89 EPS. The business’s revenue was up 4.5% compared to the same quarter last year. Sell-side analysts forecast that Hologic, Inc. will post 4.27 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HOLX. Evercore ISI raised their price target on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Raymond James raised their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Leerink Partners decreased their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Royal Bank of Canada upped their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.